16Jan 2024
XNK Therapeutics AB's evencaleucel Receives Positive Scientific Recommendation from EMA's Committee for Advanced Therapi

XNK Therapeutics AB's evencaleucel Receives Positive Scientific Recommendation from EMA's Committee for Advanced Therapi

XNK Therapeutics AB announced today that Evencaleucel had received a scientific recommendation from the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA). The recommendation classifies evencaleucel as a Somatic Cell Therapy Medicinal Product (sCTMP) within the category of Advanced Therapy Medicinal Products (ATMPs). XNK's manufacturing platform for evencaleucel is well-suited for developing autologous NK cell-based drug candidates to target malignant diseases in mono- and combination therapy. This milestone marks a crucial step in XNK's regulatory approval journey, facilitating future interactions with authorities. Peter Hovstadius, XNK's Chief Medical Officer, expressed satisfaction with the EMA's scientific recommendation.

  • #family health

Like

Save

Share